SCHEMBL4875265

SCHEMBL4875265

COC(=O)N(C)c1ccc2c(c1)-c1nc(N)nc(OS(=O)(=O)c3ccc(C)cc3)c1CCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.43
NLRP3 Q96P20 2/20 0.34
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
HRH4 Q9H3N8 2/20 0.31
P2RY12 Q9H244 1/20 0.31
LMNA P02545 1/20 0.31
THRB P10828 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
CYP1A2 P05177 1/20 0.31
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875369 0.81 HRH4 (0.48) CYP2C19ALDH1A1SMN1; SMN2KEAP1NFE2L2
SCHEMBL4874612 0.80 HRH4 (0.39) HRH4
SCHEMBL2166315 0.79 ALDH1A1 (0.49) CYP2C19ALDH1A1KDM4EKEAP1NFE2L2
SCHEMBL4878194 0.77 ALDH1A1 (0.47) CYP2C19ALDH1A1KDM4EMAPK1KEAP1
SCHEMBL4876866 0.76 ALDH1A1 (0.46) CYP2C19ALDH1A1KDM4EMAPK1KEAP1
SCHEMBL4877590 0.76 CYP2C19 (0.51) CYP2C19ALDH1A1KDM4EKEAP1NFE2L2
SCHEMBL3135449 0.73 CYP2C19 (0.47) CYP2C19NLRP3ALDH1A1KEAP1NFE2L2
SCHEMBL3131985 0.73 CYP2C19 (0.47) CYP2C19ALDH1A1KEAP1NFE2L2P2RY12
SCHEMBL3128908 0.73 CYP2C19 (0.47) CYP2C19NLRP3ALDH1A1SMN1; SMN2KEAP1
SCHEMBL4876927 0.72 CYP2C19 (0.41) CYP2C19NLRP3ALDH1A1SMN1; SMN2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735411-B2 Macrocyclic benzofused pyrimidine derivatives ABBVIE INC. (US) 2014-05-27 US disclosed
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives ABBVIE INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives DPYD, TYMS, UMPS CYP2C19 685/4885NLRP3 110/4885ALDH1A1 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.